Clinical value of intraoperative interorganizational targeted injection chemotherapy for Dixon operation of advanced rectal cancer

Abstract

Objective To explore the clinical value of intraoperative interorganizational targeted injection chemotherapy (IITIC) in Dixon operation of advanced rectal cancer (ARC). Methods From June 2013 to December 2013, 53 patients who suffered from ARC and were treated by operation in our hospital were divided into group A and group B randomly. 29 patients in group A were carried out Dixon operation and IITIC, while 24 patients in group B were carried out Dixon operation only. Serum levels of tumor necrosis factor α (TNF-α), carcinoembryonic antigen (CEA) and carbohydrate antigen 242 (CA242) were measured and compared for all the patients in perioperative period. Also, Serum levels of white blood cell (WBC), platelet (PLT), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine (Cr) were measured and compared for all the patients in perioperative period. Postoperative anastomotic fistula, intra-abdominal hemorrhage, intra-abdominal abscess and death were observed and compared between group A and group B. Postoperative follow-up and survival analysis were carried out for patients in both groups. Results The serum levels of TNF-α, CEA and CA242 at each time point were significantly different both in group A and group B (P 0.05). The serum levels of WBC, ALT, AST and Cr were not statistically significant difference between group A and group B (P>0.05), while the serum levels of PLT were statistically significant difference (P 0.05). Conclusions It is safe and feasible to carry out IITIC in Dixon operation for ARC. IITIC can increase the treatment effect to operation of ARC, which also can improve patients′ prognosis. Key words: Rectal neoplasms/SU; Rectal neoplasms/DT; Intraoperative period; Tumor markers, biological